Gut,
a leading international journal from BMJ and BSG, publishes cutting-edge gastroenterology and hepatology research and reviews
Impact Factor: 24.5
Citescore: 47.4
All metrics >>
Visual Abstracts
Visual Abstracts provide summaries of the latest research in a single, visual format.
View our latest visual abstract below. See a high-resolution version of the Visual Abstract and read the full article.
Gut Commentary Series on Digestive Health and Climate Change
We are delighted to introduce to the Gut readership a compendium of nine commentaries, each summarising one, or a hybrid, of the nine educational webinars organised by the World Gastroenterology Organisation.
Latest Articles
Pancreas:
Impact of age, comorbidities and relevant changes on surveillance strategy of intraductal papillary mucinous neoplasms: a competing risk analysis23 April 2024
Correction:
Correction: Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers23 April 2024
Oesophagus:
Hypoxia-inducible factor-1{alpha} mediates reflux-induced epithelial-mesenchymal plasticity in Barretts oesophagus patients19 April 2024
Most Read Articles
Recent advances in clinical practice:
Updates to the modern diagnosis of GERD: Lyon consensus 2.05 January 2024
Guidelines:
Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update29 January 2024
Guideline:
British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy5 January 2024
Recent advances in clinical practice:
MASLD: a systemic metabolic disorder with cardiovascular and malignant complications7 March 2024
Altmetrics
Podcasts
Featured Video
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes
Conclusion: In patients with chronic liver disease and type 2 diabetes who adhered to therapy over time, GLP1 agonists may result in lower risk of MALO. This suggests that GLP1 agonists are promising agents to reduce risk of chronic liver disease progression in patients with concurrent type 2 diabetes, although this needs to be corroborated in randomised trials.
Find out more